CBER Faults Drugmaker for Implying Hemophilia Drug Allows Patients to Engage in High-Risk Activity

Drug Industry Daily
A A
CBER’s advertising and promotional labeling branch sent an untitled letter to a drugmaker in Pennsylvania saying the company overpromised the impact of its hemophilia treatment.

To View This Article:

Login

Subscribe To Drug Industry Daily